| Year |
Citation |
Score |
| 2023 |
Zhang X, Wang Y, Supekar S, Cao X, Zhou J, Dang J, Chen S, Jenkins L, Marsango S, Li X, Liu G, Milligan G, Feng M, Fan H, Gong W, et al. Pro-phagocytic function and structural basis of GPR84 signaling. Nature Communications. 14: 5706. PMID 37709767 DOI: 10.1038/s41467-023-41201-0 |
0.342 |
|
| 2023 |
Zhang X, Wang Y, Supekar S, Cao X, Zhou J, Dang J, Chen S, Jenkins L, Marsango S, Li X, Liu G, Milligan G, Feng M, Fan H, Gong W, et al. Pro-phagocytic function and structural basis of GPR84 signaling. Research Square. PMID 36824923 DOI: 10.21203/rs.3.rs-2535247/v1 |
0.349 |
|
| 2022 |
Weickhardt AJ, Lau DK, Hodgson-Garms M, Lavis A, Jenkins LJ, Vukelic N, Ioannidis P, Luk IY, Mariadason JM. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. Bmc Cancer. 22: 478. PMID 35501832 DOI: 10.1186/s12885-022-09478-4 |
0.302 |
|
| 2021 |
Choi A, Jenkins L, Mythreye K. Elucidating the Impact of Betaglycan Glycosaminoglycan Chain Modification on Ectodomain Shedding and Cell Signaling in Ovarian Cancer The Faseb Journal. 35. DOI: 10.1096/FASEBJ.2021.35.S1.04158 |
0.463 |
|
| 2018 |
Binti Mohd Amir NAS, Mackenzie AE, Jenkins L, Boustani K, Hillier MC, Tsuchiya T, Milligan G, Pease JE. Evidence for the Existence of a CXCL17 Receptor Distinct from GPR35. Journal of Immunology (Baltimore, Md. : 1950). PMID 29875152 DOI: 10.4049/jimmunol.1700884 |
0.302 |
|
| 2018 |
Serrao A, Jenkins LM, Chumanevich AA, Horst B, Liang J, Gatza ML, Lee NY, Roninson IB, Broude EV, Mythreye K. Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. Oncogene. PMID 29780169 DOI: 10.1038/s41388-018-0316-y |
0.342 |
|
| 2018 |
Singh P, Jenkins LM, Horst B, Alers V, Pradhan S, Kaur P, Srivastava T, Hempel N, Győrffy B, Broude EV, Lee NY, Mythreye K. Inhibin is a novel paracrine factor for tumor angiogenesis and metastasis. Cancer Research. PMID 29535220 DOI: 10.1158/0008-5472.CAN-17-2316 |
0.473 |
|
| 2017 |
Jenkins LM, Horst B, Lancaster CL, Mythreye K. Dually modified transmembrane proteoglycans in development and disease. Cytokine & Growth Factor Reviews. PMID 29291930 DOI: 10.1016/j.cytogfr.2017.12.003 |
0.397 |
|
| 2017 |
Chüeh AC, Tse JW, Dickinson M, Ioannidis P, Jenkins L, Tögel L, Tan B, Luk I, Dávalos-Salas M, Nightingale R, Thompson MR, Williams BR, Lessene G, Lee EF, Fairlie WD, et al. ATF3 repression of BCL-XL determines apoptotic sensitivity toHDAC inhibitors across tumour types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28611196 DOI: 10.1158/1078-0432.Ccr-17-0466 |
0.342 |
|
| 2017 |
Singh P, Jenkins L, O'Connell K, Liu Y, Nixon A, Karthikeyan M. Abstract MIP-063: DEFINING NOVEL PARACRINE FUNCTIONS FOR INHIBIN IN OVARIAN CANCER Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Mip-063 |
0.424 |
|
| 2016 |
Jenkins LM, Singh P, Varadaraj A, Lee NY, Shah S, Flores HV, O'Connell K, Mythreye K. Altering the proteoglycan state of TβRIII/Betaglycan modulates canonical Wnt/β-catenin signaling. The Journal of Biological Chemistry. PMID 27784788 DOI: 10.1074/jbc.M116.748624 |
0.447 |
|
| 2016 |
Jenkins LM, Varadaraj A, Flores H, Karthikeyan M. Abstract B15: Transforming growth factor β type III (TβRIII/Betaglycan) suppresses canonical Wnt signaling in ovarian cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Devbiolca15-B15 |
0.467 |
|
| Show low-probability matches. |